AQNEURSA Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Aqneursa, and when can generic versions of Aqneursa launch?
Aqneursa is a drug marketed by Intrabio and is included in one NDA.
The generic ingredient in AQNEURSA is levacetylleucine. One supplier is listed for this compound. Additional details are available on the levacetylleucine profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for AQNEURSA?
- What are the global sales for AQNEURSA?
- What is Average Wholesale Price for AQNEURSA?
Summary for AQNEURSA
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| What excipients (inactive ingredients) are in AQNEURSA? | AQNEURSA excipients list |
| DailyMed Link: | AQNEURSA at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for AQNEURSA
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
US Patents and Regulatory Information for AQNEURSA
AQNEURSA is protected by zero US patents and one FDA Regulatory Exclusivity.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of AQNEURSA is ⤷ Sign Up.
This potential generic entry date is based on NEW CHEMICAL ENTITY.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
FDA Regulatory Exclusivity protecting AQNEURSA
NEW CHEMICAL ENTITY
Exclusivity Expiration: ⤷ Sign Up
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Intrabio | AQNEURSA | levacetylleucine | FOR SUSPENSION;ORAL | 219132-001 | Sep 24, 2024 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
